Jörg Bäsecke

The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy

Stephen L. Abrams, Linda S. Steelman, John G. Shelton et al. · Cell Cycle · 2010 · 136 citations · Full text

Life Sciences, Cell Biology, Oncology +17

Targeting the RAF/MEK/ERK, PI3K/AKT and P53 pathways in hematopoietic drug resistance

James A. McCubrey, Linda S. Steelman, Richard A. Franklin et al. · Advances in Enzyme Regulation · 2007 · 90 citations · Full text

Medicine, Cancer Biology, Oncology +14

Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance

James A. McCubrey, Stephen L. Abrams, Giovanni Ligresti et al. · Leukemia · 2008 · 80 citations

Medicine, Hematology, Oncology +14

Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells

Stefan Horn, Ulla Bergholz, Manfred Jücker et al. · Oncogene · 2008 · 51 citations · Full text

Medicine, Cell Biology, Hematology +9

Dominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugs

Linda S. Steelman, Stephen L. Abrams, John G. Shelton et al. · Cell Cycle · 2010 · 44 citations · Full text

Life Sciences, Cell Biology, Oncology +17